BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2025.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 108470
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.108470
Table 3 The clinicopathological characteristics of the Surveillance, Epidemiology, and End Results and Chinese cohorts before and after propensity score matching, n (%)
CharacteristicsBefore PSM1
After PSM1
Before PSM2
After PSM2
No
Yes
P value
No
Yes
P value
No
Yes
P value
No
Yes
P value
Total282284514420442041429172411631163
ELN, mean ± SD22.18 ± 9.9223.36 ± 10.69< 0.00122.52 ± 10.1523.40 ± 10.72< 0.00119.98 ± 8.2819.79 ± 7.590.50219.68 ± 7.8319.97 ± 7.640.368
Size, mean ± SD5.55 ± 3.506.13 ± 3.66< 0.0016.08 ± 3.886.13 ± 3.520.5685.21 ± 2.155.46 ± 2.230.0025.23 ± 2.155.28 ± 2.080.58
Age< 0.0010.658< 0.0010.834
20-647144 (25.3)2769 (61.3)2438 (58.0)2459 (58.5)681 (47.7)1203 (69.8)666 (57.3)660 (56.7)
Sex< 0.0010.1690.0970.474
Male13274 (47.0)2312 (51.2)2128 (50.6)2192 (52.1)796 (55.7)1012 (58.7)673 (57.9)691 (59.4)
Grade< 0.0010.9610.9
Grade 3/45395 (19.1)1126 (24.9)1025 (24.4)1028 (24.5)179 (12.5)216 (12.5)145 (12.5)142 (12.2)
Histology0.2550.4360.0020.164
Adenocarcinoma24161 (85.6)3835 (85.0)3610 (85.9)3591 (85.4)1238 (86.6)1445 (83.8)1011 (86.9)981 (84.4)
Mucinous adenocarcinoma3627 (12.8)595 (13.2)531 (12.6)535 (12.7)164 (11.5)261 (15.1)138 (11.9)169 (14.5)
Others440 (1.6)84 (1.9)63 (1.5)78 (1.9)27 (1.9)18 (1.0)14 (1.2)13 (1.1)
T stage< 0.0010.6410.270.525
T43167 (11.2)1655 (36.7)1369 (32.6)1348 (32.1)402 (28.1)517 (30.0)336 (28.9)351 (30.2)


Write to the Help Desk